Flowserve ((FLS)) has held its Q1 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Flowserve’s latest earnings call struck a cautiously optimistic tone, as management highlighted strong margin expansion, double‑digit EPS growth and resilient aftermarket demand despite softer revenue and bookings. Executives acknowledged near‑term pressure from Middle East disruptions, lower original equipment volumes and seasonal cash usage, but expressed confidence that operational gains and a solid backlog will support improved performance in the second half.
Margin Expansion and Earnings Power
Flowserve underscored notable profitability gains, with adjusted operating margin rising 230 basis points to 15.1% and adjusted gross margin up 370 basis points to 37.2%. Adjusted EPS climbed 18% to $0.85 versus the prior year, marking the 13th straight quarter of year‑over‑year gross margin expansion and reinforcing the company’s progress on pricing, mix and efficiency.
Aftermarket Strength Anchors Performance
Aftermarket activity remained a bright spot, with bookings reaching $680 million, the eighth consecutive quarter above the $600 million mark. Aftermarket sales increased 4% year over year, supported by higher capture rates across Flowserve’s installed base, giving the company a more stable revenue stream as original equipment orders ebb and flow.
Segment Margins Move Higher
Both major segments delivered improved profitability, with Flowserve’s pump division lifting adjusted gross margin by 300 basis points to 37.7% and operating margin by 140 basis points to 19.1%. The flow control division posted even sharper gains, with adjusted gross margin up 480 basis points to 35.2% and operating margin up 370 basis points to 15.9%, underscoring broad‑based cost and mix improvements.
Bookings and Backlog Remain Supportive
Despite year‑over‑year declines, the company’s order book stayed healthy, as total bookings reached $1.15 billion and the overall book‑to‑bill ratio registered 1.07 times. Book‑to‑bill in the pump division was 1.04 times and climbed to 1.4 times in the flow control division, signaling that backlog continues to build, providing visibility into future revenue.
Nuclear Wins and Project Pipeline
Management highlighted growing momentum in nuclear work, with more than $110 million of nuclear awards secured in the quarter, including two projects above $20 million. They described a robust 12‑month project funnel that has historically delivered roughly $100 million of nuclear‑related bookings per quarter, helping underpin a backlog that supports longer‑term revenue growth.
Balance Sheet Strength and Cash Ambitions
Flowserve’s leverage profile continued to improve, with net leverage reduced to about 1.2 times by quarter end, aided by steady profitability. The company also amended its credit agreement, extending the maturity by five years and expanding revolver capacity, and reiterated its goal for full‑year free cash flow conversion at or above 90% of adjusted net earnings.
Operational Excellence and 80/20 Initiatives
The Flowserve Business System and its 80/20 operational program are central to the company’s margin story, driving SKU reductions, inventory optimization and more reliable supply chains. Management pointed to ongoing footprint rationalization and roofline consolidation as structural moves aimed at sustaining cost savings and enhancing long‑term profitability.
Guidance Reaffirmed Despite Choppy Start
Management reaffirmed full‑year guidance, calling for adjusted EPS between $4.00 and $4.20, with the midpoint implying roughly 13% growth over the prior year and about 100 basis points of operating margin expansion. They continue to expect total sales growth of 3% to 6%, with acquisitions contributing around 300 basis points, even as organic growth ranges from slightly negative to modestly positive.
Revenue and Bookings Under Near‑Term Pressure
Headline revenue and orders were weaker, with Q1 revenue down 7% to $1.1 billion and total bookings falling 6% from last year. Original equipment revenue declined 18%, while revenue in the flow control division dropped 10% and pump division revenue slipped 5%, reflecting mix shifts, timing of projects and operational simplification efforts.
Impact of Middle East Disruptions
The conflict in the Middle East weighed on results, disrupting logistics and site access and leading to an estimated $50 million bookings headwind in the quarter. Management said these issues shaved roughly 200 basis points off sales and reduced EPS by about $0.06 in Q1, with a further approximate $0.07 impact contemplated for the rest of the year if conditions persist.
Seasonal Cash Use and Working Capital Strain
Cash generation was weak, with operations consuming $43 million in the first quarter, a seasonal pattern that management characterized as expected and slightly affected by Middle East challenges. They emphasized that Q1 is typically the company’s softest cash quarter, and they anticipate working capital dynamics and cash flow to improve over the balance of the year.
One‑Time Items Cloud Comparisons
Quarterly results were influenced by several non‑recurring factors, including a $0.19 benefit from tariff refunds and a negative $0.06 impact from a Latin American tax issue. When combined with the $0.06 drag from the Middle East, these items created a net $0.07 benefit to adjusted EPS, making year‑over‑year comparisons and run‑rate assessment more complicated for investors.
80/20 Simplification Weighs on OE Revenue
The same 80/20 initiative that is improving margins has also pressured near‑term original equipment sales, as SKU and model reductions slowed shipments. These changes, along with a backlog increasingly weighted toward nuclear work, led to lower OE revenue, particularly in the flow control division, where 80/20‑related actions were a key factor in its 10% revenue decline.
Lower Backlog Conversion Rates
Flowserve entered the year expecting to convert about 76% of its year‑end backlog into revenue, below its historical mid‑ to high‑range conversion levels. The company attributed this to a growing mix of large nuclear projects, which tend to have longer execution timelines and thus slow near‑term revenue recognition even as they support multiyear growth.
Visibility Limits and Q2 Outlook
The company cautioned that quarter‑to‑quarter visibility remains limited, especially with ongoing Middle East uncertainty, and assumed that disruptions continue without significant escalation. Management guided that Q2 sales will likely decline in the low‑ to mid‑single digits versus last year, with Q2 earnings expected to be broadly similar to Q1, reflecting a measured stance on near‑term performance.
FCD Margins Sensitive to Volume and One‑Offs
Within the flow control division, margins benefited from the tariff recovery in Q1, and management noted that excluding that one‑time item, margin improvement was more modest. They emphasized that segment profitability remains sensitive to volume fluctuations and the near‑term impact of 80/20 actions, suggesting some volatility until volumes normalize and simplification benefits fully materialize.
Reaffirmed Guidance and Outlook
Looking ahead, Flowserve reaffirmed its 2026 guidance anchored by adjusted EPS of $4.00 to $4.20, assuming mid‑single‑digit bookings growth and total sales expansion of 3% to 6%. The outlook factors in an ongoing, but manageable, impact from Middle East disruptions, integration of acquisitions such as the expected Trillium closing and free cash flow conversion of at least 90% of adjusted net earnings, supported by a strengthened balance sheet.
Flowserve’s call painted a picture of a company navigating near‑term turbulence while steadily improving its underlying economics through operational discipline and a growing project backlog. Investors will be watching how quickly backlog converts, how Middle East risks evolve and whether the margin gains can be sustained, but management’s confidence in meeting its multi‑year targets suggests a constructive setup for patient shareholders.

